MRI radiomic signature predicts intracranial progression-free survival in patients with brain metastases of ALK-positive non-small cell lung cancer
Shijun Zhao(Second Hospital of Shandong University), Ning Wu(Regeneron (United States)), Yujing Jin(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Song(Xuzhou Medical College), Lv Lv(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaomin Zheng(Tsinghua University), Xiaoqing Liu(Fujian Medical University), Li Mao(Army Medical University), Sicong Wang(Griffith University), Qi Sun(First Affiliated Hospital of Xi'an Jiaotong University), Lieming Ding(Betta Pharmaceuticals (China)), Lina Zhou(Nanjing University of Chinese Medicine), Xiuli Tao(Chinese Academy of Medical Sciences & Peking Union Medical College), Donghui Hou(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 29
Related Papers
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy
|Clinical Cancer Research|2018|198
Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations
|Cell Metabolism|2023|191
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
|The Lancet Respiratory Medicine|2021|183